Apligraf
Increasing cases of Diabetes
The World Health Organization (WHO) reports that non-communicable diseases caused 74% of deaths in 2019; diabetes killed 1.6 million people, making it the ninth largest cause of death worldwide.
Increase Incidences of Burns, Accidents, Injuries
The WHO estimates that every year road traffic accidents claim the lives of over 1.3 million people. Between 20 and 50 million additional people have non-fatal injuries, with many of them becoming disabled as a result.
Market Segmentation
Global Regenerative Wound Care Market can be segmented by type, by wound type, by end user and by region. Based on type, the market can be categorized into autologous stem cells, biological skin substitutes, tissue/multiple tissue platform, fetal skin, regenerative wound care devices, and others. Based on wound type, the market can be fragmented into ulcers, surgical & traumatic wounds, and burns. Ulcers can further be divided into diabetic foot ulcers, pressure ulcers, and others. Based on end user, the market can be grouped into hospitals, ambulatory surgical centers, burn care centers & wound clinics, and others. Regionally, the market can be segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa.
Market Players
DeCell Technologies Inc., Avita Medical, Inc., Organogenesis, Inc., Histogen, Inc., RenovoDerm (Nanofiber Solutions, LLC), StemsysBio, Koninklijke DSM N.V., MiMedx Group, Inc., among others are some of the leading players operating in the global regenerative wound care market.
Recent Developments
Global Regenerative Wound Care Market is witnessing a lot of new developments in the form of mergers & acquisitions, new product launches, launching new clinical trials, increasing research & development activities, making investments, among others in order to stay competitive and have an edge over the other players operating in the market.
In June 2021, MiMedx Group, Inc. received approval for the commercialization of its product Epifix in Japan by the Japanese Ministry of Health, Labour and Welfare.
In May 2019, Organogenesis Inc. entered into an agreement with Vizient, Inc. This in turn helped Organogenesis increase its wound care product offerings and improve its market positioning.
Attribute | Details |
Base Year | 2022 |
Historic Data | 2018 – 2021 |
Estimated Year | 2023 |
Forecast Period | 2024 – 2028 |
Quantitative Units | Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028 |
Report coverage | Revenue forecast, volume forecast, company share, competitive landscape, growth factors, and trends |
Segments covered | · By Type · By Wound Type · By End User · By Region |
Regional scope | North America, Europe, Asia Pacific, South America, Middle East & Africa |
Key companies profiled | DeCell Technologies Inc., Avita Medical, Inc., Organogenesis, Inc., Histogen, Inc., RenovoDerm (Nanofiber Solutions, LLC), StemsysBio, Koninklijke DSM N.V., MiMedx Group, Inc. |
Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |